TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02959437
Drug: INCB059872
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Study: NCT02486328
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage adjustment
Study: NCT01143948
Drug: Glargine & Glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal Glargine \& bolus Glulisine
Study: NCT01143948
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale regular insulin
Study: NCT01143948
Drug: NPH & regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal NPH \& bolus regular insulin
Study: NCT01494402
Drug: Buffered acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04053764
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
Study: NCT01592409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
Study: NCT01734681
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00790738
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04325659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
Study: NCT00890955
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
Study: NCT00220766
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03185611
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: immunomodulator
Study: NCT04551170
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral theophylline
Study: NCT04551170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule or elixir
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Study: NCT04213196
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
Study: NCT02232893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
Study: NCT02242747
Drug: 5% 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: two applications a day for four weeks in a pre-determined area
Study: NCT01044004
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 150mg/day for 13 weeks
Study: NCT04721054
Drug: Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Study: NCT04721054
Drug: general anesthesia effect on heart rate in Laparoscopic Cholecystectomy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
Study: NCT02293538
Drug: FID 114657 eye drops (10 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
Study: NCT02293538
Drug: Saline control eye drops (15 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline eye drops (15 ml)
Study: NCT02697253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours.
Study: NCT02040480
Drug: GSK2110183 IR Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
Study: NCT00987974
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20 mg/day for 3 days.
Study: NCT00987974
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 3 days.
Study: NCT00987974
Drug: rosuvastatin 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/day for 7 days
Study: NCT00987974
Drug: placebo 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 7 days
Study: NCT04139395
Drug: 68Ga-Citrate PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
Study: NCT01297062
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo (matching volume of placebo)
Study: NCT01694537
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
Study: NCT01694537
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is made with same size and shape with study drug.
Study: NCT00003135
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003135
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02967302
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control
Study: NCT01714128
Drug: Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES-PET/CT imaging
Study: NCT03119857
Drug: Antiandrogen
Normalized name: Antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01604330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
Study: NCT03371420
Drug: PU-AD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00755482
Drug: Aquamin F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755482
Drug: Placebo (maltodextran)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03491553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
Study: NCT03491553
Drug: Hepatitis B virus (HBV) OAV Therapy
Normalized name: hepatitis B virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)
Study: NCT00157937
Drug: Comparator: theophylline ER/Duration of Treatment: 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01025817
Drug: mycophenolate mofetil and tacrolimus
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
Study: NCT02959996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection in the Pfannenstiel incision
Study: NCT00039195
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00039195
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02754830
Drug: LY3303560 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02754830
Drug: Saline Solution - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02754830
Drug: LY3303560 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01996748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two administrations daily for 7 days
Study: NCT02268006
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03000387
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patches of 21 mg, 14 mg and 7 mg
Study: NCT02242825
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00679731
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5.0 to 25 mg weekly
Study: NCT02205606
Drug: HGP0816 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT02205606
Drug: HGP0816 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT02205606
Drug: HGP0816 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT02205606
Drug: HCP1306 5/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT02205606
Drug: HCP1306 10/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT02205606
Drug: HCP1306 20/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O.
Study: NCT00059722
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00059722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00059722
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03972488
Drug: 2.5% Lys-Arg sterile amino acid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
Study: NCT00121992
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00121992
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01597427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo solution.
Study: NCT00414960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po QD for 6 months
Study: NCT01600768
Drug: Beta-Lactams
Normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion time: 30 mins or 1 hr
Study: NCT01600768
Drug: Beta-Lactams
Normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion time 4 hrs
Study: NCT01763281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004038
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00511524
Drug: [carbonyl-^11C]GW842166
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
Study: NCT02713191
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
Study: NCT03733873
Drug: Suoquan
Approvals — FDA: no, EMA: no, PMDA: no
Description: take Suoquan mixture for 3 months
Study: NCT03936517
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
Study: NCT03936517
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
Study: NCT04123717
Drug: Intravenous Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
Study: NCT03089216
Drug: 8% arginine and calcium carbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: using during all the treatment.
Study: NCT00259220
Drug: erythomycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erythomycin
Study: NCT00706667
Drug: Ferinject ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
Study: NCT00622869
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
Study: NCT03177980
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
Study: NCT02487225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
Study: NCT03177980
Drug: Fentanyl and clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
Study: NCT01918995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT02213302
Drug: placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04425564
Drug: metronomic XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03976115
Drug: DDO-3055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03976115
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01317615
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
Study: NCT01287533
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monthly dosage of ibandronate 150mg
Study: NCT01287533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: monthly dosage of placebo
Study: NCT00006248
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00703755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03996434
Drug: Antagonist
Normalized name: Purine antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix acetate 0.25 mg
Study: NCT02456857
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01983774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT04564872
Drug: HSK7653 10 mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
Study: NCT04564872
Drug: HSK7653 25 mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
Study: NCT01445938
Drug: SAR97276A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular
Study: NCT04480697
Drug: HPG1860
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects randomized to active compound and 2 subjects randomized to placebo
Study: NCT00005834
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
Study: NCT03000374
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
Study: NCT03000374
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study: NCT00625898
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study: NCT02517320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03121833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500ml 0.9% sodium chloride
Study: NCT03121833
Drug: AIM regimen / GT regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)
Study: NCT02101840
Drug: OxyNEO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
Study: NCT02101840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
Study: NCT00228150
Drug: SR57667B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02920515
Drug: Triptorlin or Leuprorelin
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin releasing hormone agonists (GnRHa)
Study: NCT02920515
Drug: Zhibo dihuang pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine
Study: NCT02920515
Drug: Dabu ying pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine
Study: NCT02375958
Drug: PCA062
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00484536
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, once daily
Study: NCT00789958
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT
Study: NCT00074724
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
Study: NCT02622724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for investigational drug